Certa Therapeutics’ FT011 Granted US FDA Fast Track for the Treatment of Systemic Sclerosis MELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with inflammatory and fibrotic...

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma Clinical trial data from a multi-national, double-blinded trial of FT011 being developed for the treatment of systemic sclerosis (scleroderma) presented at the American College of Rheumatology Annual...